Ocugen (OCGN) Current Leases (2018 - 2026)
Ocugen's (OCGN) quarterly Current Leases came in at $850000.0 in Q1 2026, up 15.49% YoY from $736000.0 in Q1 2025, and down 0.93% on a QoQ basis from $858000.0 in Q4 2025.
Ocugen (OCGN) Current Leases (2018 - 2026) Analysis & Trends
Ocugen (OCGN) has 9 years of Current Leases data on file, last reported at $850000.0 in Q1 2026.
- Quarterly Current Leases rose 15.49% year-over-year to $850000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $850000.0 (up 15.49% YoY) and the FY2025 annual result came in at $858000.0, up 65.32% from the prior year.
- Current Leases fell to $850000.0 in Q1 2026, from $858000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $858000.0 in Q4 2025 to a low of $254000.0 in Q1 2022.
- A 5-year average of $579941.2 and a median of $526000.0 in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases soared 157.56% — and 2024, when it fell 12.36%.
- Tracing OCGN's Current Leases over 5 years: stood at $498000.0 in 2022, then climbed by 15.26% to $574000.0 in 2023, then dropped by 9.58% to $519000.0 in 2024, then soared by 65.32% to $858000.0 in 2025, then decreased by 0.93% to $850000.0 in 2026.
- The last three Current Leases figures came in at $850000.0 (Q1 2026), $858000.0 (Q4 2025), and $855000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 839,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 839,000.00 |
| Mar 31, 2026 | 850,000.00 |
| Dec 31, 2025 | 858,000.00 |
| Sep 30, 2025 | 855,000.00 |
| Jun 30, 2025 | 853,000.00 |
| Mar 31, 2025 | 736,000.00 |
| Dec 31, 2024 | 519,000.00 |
| Sep 30, 2024 | 477,000.00 |
| Jun 30, 2024 | 461,000.00 |
| Mar 31, 2024 | 589,000.00 |
| Dec 31, 2023 | 574,000.00 |
| Sep 30, 2023 | 540,000.00 |
| Jun 30, 2023 | 526,000.00 |
| Mar 31, 2023 | 512,000.00 |
| Dec 31, 2022 | 498,000.00 |
| Sep 30, 2022 | 443,000.00 |
| Jun 30, 2022 | 314,000.00 |
| Mar 31, 2022 | 254,000.00 |
| Dec 31, 2021 | 363,000.00 |
| Sep 30, 2021 | 172,000.00 |